Cochlear was founded in 1981 and is headquartered in Sydney, Australia. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss, and the company actively targets the growing cohort of seniors in developed markets. In April 2022, Cochlear acquired Danish competitor Oticon Medical for A$170 million.
Cyborg Score Rationale
Cochlear holds approximately 60% of the global cochlear implant market. The company demonstrates strong competitive positioning with established market dominance, a global distribution network across 180+ countries, and a consistent revenue base of ~$1.5B+. However, regulatory scrutiny and emerging competitors in adjacent hearing solutions present ongoing challenges.
Top Insights
Dominant 60% global market share in cochlear implants with over 650,000 devices implanted to date
Geographic diversification with developed markets (80% revenue) offering stability while emerging markets present growth opportunity
Recent strategic acquisition of Oticon Medical (2022) expands product portfolio and competitive positioning
Global workforce of 5,500 employees across manufacturing facilities in Sweden, China, Malaysia, and Australia
Named Competitors
MED-EL — Austrian cochlear implant and hearing device manufacturer